On July 10, Ali Health rose 3.53% in regular trading, trading at HK$3.52 per share, with turnover of approximately HK$95.38 million.

On the news front, the medical e-commerce sector staged a collective rebound, with peer JD Health up 3.62%, PA Good Doctor up 3.66%, and parent company Alibaba-W up 3.98%, providing broad-based sector support. Additionally, the innovative drug first-launch platform effect continues to gain momentum, with Simcere Pharmaceutical's Yingtaiqing Arginine Ibuprofen Tablets and Shuangjing's 1200IU Vitamin D Drops both exclusively debuting on Ali Health's platform, reinforcing the company's positioning as a premier launch destination for new and specialty drugs.

For broader context, the company recently reported fiscal year revenue of RMB 34.255 billion with net profit growth of 35.2% year-over-year, while announcing a proposed share buyback authorization of up to 10% of issued shares and dividend distributions totaling RMB 0.1945 per share, signaling continued shareholder return commitment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)